Novel antimicrobials and infectious disease practice: Research updates from ID Week 2019

Details

Antimicrobial resistance (AMR) is a phenomenon fueled by the selection pressure leveled against microorganisms through the use and misuse of antimicrobials in clinical and agricultural settings as well as horizontal gene transfer between pathogens. The WHO predicts that there will be 50 million deaths caused by infectious diseases, and the U.N. General Assembly has designated the emergence of AMR the largest world health problem.

The World Health Assembly has endorsed a Global Action Plan on Antimicrobial Resistance, including one step to address AMR: the sustainable investment in and development of new antimicrobials. Helping the clinician discern the role of these advances merits continuing healthcare professional education, as research suggests that HCPs are oftentimes unable to keep up with the steady publishing of literature and evolution of clinical practice. In so doing, the goal is to educate clinicians about the appropriate role of novel antibiotics so that they may more effectively address the challenge of AMR rather than contributing to it.

Target Audience:

HCPs specializing in: Infectious disease, critical care, and primary care; physician assistants, nurse practitioners, nurses, and pharmacists who practice in the aforementioned areas of specialty; and any other healthcare professionals with an interest in or who treat patients with antimicrobials.

By the end of the session the participant will be able to:

• Identify key findings from the ID Week 2019 conference.
• Apply the changes in CAP guidelines 2019 from 2007.
• Identify novel drugs approved in 2019 and their potential.
• Understand the implications of some current research and paradigm shifts.
• Review HIV progress in the last year.